Preoperative Treatment With Cetuximab and/or IMC-A12

PHASE2CompletedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

October 17, 2011

Primary Completion Date

August 15, 2018

Study Completion Date

August 15, 2018

Conditions
Head and Neck Squamous Cell Carcinoma
Interventions
DRUG

Cetuximab

First dose of 400 mg/m\^2 by vein on Days 1 and 8 over 2 hours, second dose of 250 mg/m\^2 on week 2 and 3 (if applicable) given over 1 hour.

DRUG

IMC-A12

6 mg/kg/week by vein on Days 1 and 8 over 1 hour on weeks 1 and 2 and 3 (if applicable).

PROCEDURE

Surgical tumor resection

Surgical tumor resection on Day 10.

Trial Locations (1)

77030

University of Texas MD Anderson Cancer Center, Houston

All Listed Sponsors
collaborator

Eli Lilly and Company

INDUSTRY

lead

M.D. Anderson Cancer Center

OTHER

NCT00957853 - Preoperative Treatment With Cetuximab and/or IMC-A12 | Biotech Hunter | Biotech Hunter